Navigation Links
Arbor Pharmaceuticals Completes $34.8 Million Financing

ATLANTA, Nov. 11, 2010 /PRNewswire/ -- Arbor Pharmaceuticals, a specialty pharmaceutical company based in Atlanta, GA, announced today the completion of a $34.8 million financing.  This financing included a $17.5 million investment in the form of Series B Preferred Stock led by Signet Healthcare Partners, LLC.  The remainder of the financing was in the form of a term loan provided by several of the investing parties.  Also participating in both the Series B equity investment and the loan were existing Arbor shareholders, JW Asset Management, LLC and ARCH Healthcare Fund, which are led by Jason Wild and Allen Chao respectively.  

Ed Schutter, President and CEO of Arbor commented, "We are pleased with the commitment to Arbor demonstrated by our Series B investors. We have already completed several product license or acquisition agreements in the six months since the acquisition of Arbor by our original investment team and expect to use this funding to acquire other products."

Jim Gale, Managing Director of Signet Healthcare Partners added, "Arbor Pharmaceuticals has grown tremendously in the past year.  We expect them to continue this impressive growth rate for the foreseeable future.  This infusion of capital will enable Arbor to acquire other products positioning it to become a leading specialty pharmaceutical company."

Jason Wild, Chairman of the Board of Arbor added, "We are pleased to be adding Signet, with its industry expertise, to the Arbor shareholder base.  Arbor has an established national sales force with 75 professionals and we expect revenues to exceed $100 million in 2011. We are very pleased with this progress as it surpasses the near term goals we had established when we acquired the Company in April 2010."

About Arbor Pharmaceuticals, Inc.

Arbor Pharmaceuticals, headquartered in Atlanta, Georgia, is a specialty pharmaceutical company currently focused primarily on the growing pediatric market. The company intends to become a leading specialty pharmaceutical company by actively licensing, developing and commercializing late-stage products for specialty focused conditions. Arbor currently markets three products for varying otic conditions including XYLAREX®, ZINOTIC® and NEOTIC®, and also markets PEDIADERM™ HC COMPLETE KIT for atopic dermatitis, FLUORADAY® for fluoride supplementation, and RHINARIS® and SALTAIRE® for nasal hygiene.

For more information regarding Arbor Pharmaceuticals or any of its products, visit or send email inquiries to

About JW Asset Management, LLC

JW Asset Management is a New York based fund manager for three investment partnerships. Jason Wild, a registered pharmacist, is the firm's founder and chief investment officer. JW Asset Management was founded in 1997 and has a strong history of finding opportunities within the specialty pharmaceutical sector. The firm is active in both the public and private equity markets.

About Signet Healthcare Partners

Signet Healthcare Partners was founded in 1998 and has a team that brings over 100 years of collective experience in the biopharmaceutical, medical device, private equity and investment banking businesses. Signet Healthcare has maintained its dedicated focus to diversified healthcare investing – primarily serving as lead investor to expansion stage companies engaged in specialty pharmaceuticals, medical devices and biopharmaceutical services.

About ARCH Healthcare Fund

ARCH Healthcare Fund is a California based firm with investments in both Asia and the United States.  ARCH has professionals working in the U.S., Taiwan, and Hong Kong.  Dr. Allen Chao, the founder and former CEO of Watson Pharmaceuticals is the Managing Partner.  ARCH Healthcare is dedicated to diversified healthcare investing, primarily in expansion stage companies engaged in specialty pharmaceuticals, medical devices, healthcare services and biopharmaceutical services.

SOURCE Arbor Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. DATATRAK Secures Safe Harbor Certification for EU and Switzerland
2. Quantum Signal and Delphinus Medical Technologies Awarded MEGA Funding to Expand in Ann Arbor Area
3. Arbor Pharmaceuticals Announces the Launch of Pediaderm(TM) HC Complete Kit - A Comprehensive Approach to the Management of Atopic Dermatitis
4. Harbor BioSciences to Receive Patent for Apoptone(R) Cancer Treatment
5. Hollis-Eden Announces Name Change to Harbor BioSciences, Inc. and Ticker Symbol Change to HRBR
6. Cold Spring Publishing, LLC, Changes Name to Harborside Press, LLC
7. Harborside Healthcare to Pay U.S. $1.375 Million to Resolve Allegations of Kickbacks and Sham Durable Medical Services
8. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
9. Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for First Quarter Fiscal 2011
10. Aires Pharmaceuticals, Inc. Completes $20M Equity Financing and Signs an Option Agreement with a Major Pharmaceutical Company
11. Access Pharmaceuticals Presents CobOral™ Insulin Research at 10th Annual Diabetes Technology Meeting on November 11-13, 2010
Post Your Comments:
(Date:11/25/2015)... THOUSAND OAKS, Calif. , Nov. 25, 2015 /PRNewswire/ ... of a Biologics License Application (BLA) with ... Administration (FDA) for ABP 501, a biosimilar candidate to ... the first adalimumab biosimilar application submitted to the FDA ... biosimilar pathway. Sean E. Harper , M.D., ...
(Date:11/25/2015)... On Tuesday, November 24, 2015, the ... Wright Medical Technology, Inc. for product liability and ... implant device, awarded $11 million in favor of ... and three days of deliberations, the jury found ... designed and unreasonably dangerous, and that Wright Medical ...
(Date:11/25/2015)... -- Allergan plc (NYSE: AGN ) today announced that ... York State Attorney General,s Office to end the ... statutes with the Attorney General over the decision of Forest ... selling the now generic version of memantine immediate release tablets.  ... released its counterclaims against New York , ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... the way that they are handling security in light of the recent terrorist attacks ... in an attempt to stop an attack from reaching U.S. soil. Especially around special ...
(Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss ... to treat it. Surviving Mesothelioma has just posted the findings on the website. ... Zurich analyzed the cases of 136 mesothelioma patients who were treated with chemotherapy followed ...
(Date:11/27/2015)... ... November 27, 2015 , ... "When ... said an inventor from Hillside, N.J. "Many people catch diseases simply from sitting ... individuals will always be protected from germs." , He developed the patent-pending QUDRATECS ...
(Date:11/27/2015)... ... ... The print component of “Supporting Our Caregivers” is distributed ... Minneapolis, South Florida, with a circulation of approximately 250,000 copies and an estimated ... media strategy and across a network of top news sites and partner media ...
(Date:11/27/2015)... ... ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of its ... 3.7 billion people under the age of 50 – or 67% of the population - ... estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle Li, ...
Breaking Medicine News(10 mins):